Equity Overview
Price & Market Data
Price: $7.74
Daily Change: -$0.16 / 2.07%
Range: $7.61 - $7.89
Market Cap: $784,479,936
Volume: 724,455
Performance Metrics
1 Week: 13.16%
1 Month: -4.68%
3 Months: -36.61%
6 Months: -46.47%
1 Year: -53.49%
YTD: -38.91%
Company Details
Employees: 181
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.